Clinical Pharmacology in HIV Therapy

Mohamed Atta, Sophie De Seigneux, Gregory M Lucas

Research output: Contribution to journalArticle

Abstract

The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.

Original languageEnglish (US)
Pages (from-to)435-444
Number of pages10
JournalClinical journal of the American Society of Nephrology : CJASN
Volume14
Issue number3
DOIs
StatePublished - Mar 7 2019

Fingerprint

Clinical Pharmacology
HIV
HIV-1
Anti-Retroviral Agents
Morbidity
Therapeutics
Mortality
Drug Combinations
Comorbidity
Safety

Keywords

  • Anti-Retroviral Agents
  • antiretroviral therapy
  • Attention
  • Clinical
  • Comorbidity
  • drug interactions
  • drug nephrotoxicity
  • Health Services Accessibility
  • HIV
  • HIV Infections
  • HIV-1
  • Morbidity
  • pharmacokinetics
  • Pharmacology

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Clinical Pharmacology in HIV Therapy. / Atta, Mohamed; De Seigneux, Sophie; Lucas, Gregory M.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 14, No. 3, 07.03.2019, p. 435-444.

Research output: Contribution to journalArticle

@article{83c3dc825d5e4de787977adfd52d3df7,
title = "Clinical Pharmacology in HIV Therapy",
abstract = "The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.",
keywords = "Anti-Retroviral Agents, antiretroviral therapy, Attention, Clinical, Comorbidity, drug interactions, drug nephrotoxicity, Health Services Accessibility, HIV, HIV Infections, HIV-1, Morbidity, pharmacokinetics, Pharmacology",
author = "Mohamed Atta and {De Seigneux}, Sophie and Lucas, {Gregory M}",
year = "2019",
month = "3",
day = "7",
doi = "10.2215/CJN.02240218",
language = "English (US)",
volume = "14",
pages = "435--444",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "3",

}

TY - JOUR

T1 - Clinical Pharmacology in HIV Therapy

AU - Atta, Mohamed

AU - De Seigneux, Sophie

AU - Lucas, Gregory M

PY - 2019/3/7

Y1 - 2019/3/7

N2 - The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.

AB - The success of combination antiretroviral therapy in the treatment of HIV-1-positive individuals has shifted clinical attention toward combination antiretroviral drug regimens that optimize tolerability, long-term safety, and durable efficacy. Wherever patients have access to treatment, morbidity and mortality are increasingly driven by non-HIV-associated comorbidities, which may be observed earlier than in age-matched controls and despite the best available combination antiretroviral therapy. Similarly, HIV-1-positive individuals are now diagnosed and treated earlier with anticipated lifelong therapy. The contribution of specific antiretroviral agents to long-term morbidity and mortality is dependent on the pharmacologic characteristics of these agents, and it is increasingly important in this context.

KW - Anti-Retroviral Agents

KW - antiretroviral therapy

KW - Attention

KW - Clinical

KW - Comorbidity

KW - drug interactions

KW - drug nephrotoxicity

KW - Health Services Accessibility

KW - HIV

KW - HIV Infections

KW - HIV-1

KW - Morbidity

KW - pharmacokinetics

KW - Pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85062607092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062607092&partnerID=8YFLogxK

U2 - 10.2215/CJN.02240218

DO - 10.2215/CJN.02240218

M3 - Article

C2 - 29844056

AN - SCOPUS:85062607092

VL - 14

SP - 435

EP - 444

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 3

ER -